- In November 2023, BD introduced the PIVOT Pro Needle-free Blood Collection Device, designed to work seamlessly with both integrated and long peripheral IV catheters. This innovative product aligns with BD's vision of achieving a "One-Stick Hospital Stay," aiming to enhance patient comfort and streamline blood collection procedures. The launch highlights BD's commitment to improving healthcare efficiency through advanced medical technologies
- In September 2023, PharmaJet, known for its precision delivery systems, announced encouraging results from Scancell's Phase 2 clinical trial targeting patients with unresectable advanced melanoma. The trial utilized the PharmaJet Stratis System for needle-free injection, which has emerged as a favored method among patients. This positive data reinforces the effectiveness of needle-free technology in enhancing patient experience and treatment outcomes
- In September 2023, the Indian government launched GEMCOVAC-OM, a COVID-19 booster vaccine specifically designed with mRNA targeting the Omicron variant. Administered intradermally through a needle-free injector, this thermostable vaccine demonstrated enhanced immune responses in study participants. The innovative delivery method contributes to its effectiveness, marking a significant advancement in vaccination strategies
- In August 2023, Pulse Needle Free Systems launched the first-ever line of disposable needle-free vaccination equipment for animals. Priced comparably to traditional syringes and needles, these innovative devices offer significant health and food safety benefits for pig farmers. This development marks a notable advancement in veterinary vaccination methods, enhancing efficiency and reducing the risk of infection
- In June 2023, PharmaJet partnered with Zydus Lifesciences to successfully administer the world’s first plasmid DNA COVID-19 vaccine utilizing its Tropis system. This innovative delivery method has demonstrated enhanced immune responses and improved clinical effectiveness. This collaboration marks a significant milestone in vaccine technology, showcasing the potential of needle-free delivery systems in combating infectious diseases
Frequently Asked Questions
The market is segmented based on Segmentation, By Design Type (Straight Channel, T-Channel, Y-Channel, and Multi-Channel), Mechanism (Positive, Negative, and Neutral), Dwell Time (Seven-Day and Other Than Seven-day), End-User (Hospitals, Ambulatory Surgical Centers, and Others) – Industry Trends and Forecast to 2031
.
The Global Needle Free Iv Connectors Market size was valued at USD 920.86 USD Million in 2023.
The Global Needle Free Iv Connectors Market is projected to grow at a CAGR of 8.11% during the forecast period of 2024 to 2031.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
